View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 7, 2022

Assembly Biosciences begins Phase Ib hepatitis B infection treatment trial

The Phase Ib trial will evaluate 3733’s pharmacokinetics, antiviral activity, and safety in cHBV infection patients.

Assembly Biosciences has initiated a Phase Ib clinical trial of its investigational therapy ABI-H3733 (3733) to treat chronic hepatitis B virus (cHBV) Infection.

In preclinical studies, the next-generation core inhibitor 3733 showed significant increase in potency against covalently closed circular DNA (cccDNA) formation as well as the production of new virus compared to the first-generation inhibitors.

The double-blind, randomised, placebo-controlled, multi-centre Phase Ib clinical trial has been designed to assess the pharmacokinetics, antiviral activity, and safety of 3733 in adult patients with cHBV infection.

It builds upon the data obtained from the previous Phase Ia study which demonstrated 3733’s favourable safety and pharmacokinetic profile.

The Phase Ib trial will evaluate a new tablet formulation with the potential for a once-daily dosing.

About 50 cHBV infection patients who are treatment naïve or off treatment will be recruited for the dose-escalation trial.

Later, the subjects will be randomised into 8:2 ratio and receive the new tablet formulation of 3733 and placebo for 28 days.

The study’s objectives include changes in HBV DNA as well as other viral parameters associated with 3733.

Assembly Biosciences CEO and president John McHutchison said: “We look forward to better understanding the safety profile and impact of activity of this novel, next-generation core inhibitor candidate in patients with chronic HBV infection through this trial.

“This study initiation serves as an important milestone in the clinical development program for 3733, a promising candidate that has demonstrated increased potency against both HBV core inhibitor mechanisms and against cccDNA formation in particular and advances our strategy to pursue finite and curative HBV therapies.”

The company stated that the data from the trial will support the dose selection for a Phase II study in the future.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena